Zacks Investment Research
19 Jun 2026, 09:31 UTC · 1h ago
Biodesix (BDSX) Surges 10.5%: Is This an Indication of Further Gains?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
19 Jun 2026, 09:31 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Canaccord Genuity raised its price target for Biodesix (BDSX) from $22.00 to $27.00 while maintaining a 'Buy' rating. — A significant price target increase by a research firm typically triggers positive investor sentiment and upward price pressure.
+0.60Biodesix is expected to report revenue growth of 30.4% year-over-year for its upcoming quarterly report. — Strong top-line growth projections are a fundamental driver for valuation increases in growth-oriented medical services companies.
+0.40The consensus EPS estimate for Biodesix has been revised 4% higher over the last 30 days. — Positive earnings revisions are historically correlated with near-term stock price appreciation.
+0.30Continue reading
6 related stories
Search tags
Biodesix is expected to post a quarterly loss of $0.85 per share, a 46.9% increase in loss year-over-year. — Widening losses can act as a drag on the stock price, offsetting some of the optimism from revenue growth.
-0.20Which stocks this story touches
Shares jumped 10.5% following a price target increase by Canaccord Genuity and positive operational progress.
Shares finished the session 1.9% higher and showed modest monthly gains.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
CNBC
6h ago
